Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 3, 2009
Business Overview: IRIDEX is a provider of therapeutic-based laser systems, consumable probes, and delivery devices for ophthalmology and aesthetics. The company operates in two segments: Ophthalmology and Aesthetics. It sells products domestically via a direct sales force and internationally through approximately 100 independent distributors in 107 countries.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Oct 3, 2009 | Nine Months Ended Oct 3, 2009 |
|---|---|---|
| Revenues | $10,400 | $31,649 |
| Gross Profit | $5,122 | $14,999 |
| Gross Margin | 49.2% | 47.4% |
| Operating Income | $969 | $1,731 |
| Net Income | $646 | $2,068 |
| Diluted EPS | $0.07 | $0.23 |
| Cash and Cash Equivalents | $7,884 | $7,884 (Balance Sheet) |
| Net Cash from Operating Activities | N/A | $5,244 |
| Bank Line of Credit Outstanding | $3,500 | $3,500 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 13.2% in the quarter and 13.0% for the nine-month period compared to the prior year. The decline was driven primarily by the global economic environment impacting the Aesthetics segment (down 29.5% quarterly, 30.1% nine-month) and, to a lesser extent, the Ophthalmology segment (down 5.7% quarterly, 4.1% nine-month).
- Profitability Improvement: Despite revenue declines, the company returned to profitability. Net income for the nine months ended Oct 3, 2009, was $2.068 million, compared to a net loss of $0.867 million in the prior year period. Operating income improved from a loss of $1.225 million to income of $1.731 million.
- Margin Expansion: Gross margin improved to 49.2% (quarterly) and 47.4% (nine-month) from 41.6% in the prior year periods. This was due to a favorable product mix (higher margin ophthalmology products), reduced amortization of intangible assets previously charged to cost of revenues, and lower manufacturing expenses.
- Expense Reduction: Operating expenses decreased significantly. Sales and marketing expenses dropped 19.3% (quarterly) and 15.5% (nine-month), while General and Administrative expenses fell 30.0% (quarterly) and 27.7% (nine-month), largely due to reduced amortization, lower commissions, and decreased professional service fees.
- Legal Settlement: The company received an $800,000 legal settlement payment from Synergetics in the nine-month period, contributing to pre-tax income.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash ($7.9 million) and the Wells Fargo credit facility provide sufficient liquidity for the next 12 months. The company is currently in compliance with debt covenants. However, the credit facility is asset-based; if the borrowing base (accounts receivable and inventory) declines due to customer payment delays or defaults, borrowing capacity could be reduced.
- Economic Sensitivity: The company faces significant risk from worldwide economic slowdowns. Purchases of its products are often discretionary, particularly in the aesthetics segment, leading to delayed or canceled orders.
- Segment Trends: The aesthetics market remains in a sharp downturn. Ophthalmology recurring revenues (consumables and service) remained relatively stable, while system sales were impacted by reduced capital spending in the U.S. market, though some recovery was noted in the third quarter.
- Intellectual Property: A key "Connector Patent" protecting the interface between delivery devices and laser consoles is set to expire in the second half of 2010, which may increase competition for consumable sales.
- Internal Controls: While the material weakness identified in 2007 has been remediated, management noted significant deficiencies regarding the accounting close process, demo inventory controls, and data backup procedures.
Investor Verification Checklist
- Debt Covenant Compliance: Verify continued compliance with the Wells Fargo asset-based credit facility covenants, specifically the borrowing base calculations.
- Aesthetics Segment Recovery: Monitor the trajectory of the aesthetics segment, which has seen a >30% revenue decline, to assess if the downturn is stabilizing.
- Patent Expiration Impact: Evaluate the potential impact of the Connector Patent expiration in late 2010 on recurring consumable revenue.
- Inventory Levels: Review inventory turnover and valuation, as the company reduced inventory by $2.1 million in the nine-month period, suggesting a drawdown of excess stock.
- Internal Control Remediation: Confirm progress on remedying the noted significant deficiencies in internal controls over financial reporting.